Evaluation of an Integrated Microfinance and Depression Care Program for Women (LIFE-DM)

This study is ongoing, but not recruiting participants.
National Institute of Mental Health (NIMH)
Danang Psychiatric Hospital
Information provided by (Responsible Party):
Victoria K. Ngo, PhD, RAND
ClinicalTrials.gov Identifier:
First received: February 10, 2014
Last updated: March 3, 2015
Last verified: March 2015

The study evaluates LIFE-DM, an integrated microfinance and collaborative care intervention by comparing it to enhanced treatment as usual (national guideline antidepressant care and referral to microfinance resources) in Vietnam. Intervention effects at baseline, 6 month, and 12 month follow-up on patient outcomes, including depression, anxiety, quality of life, functioning, self-efficacy, satisfaction, and income will be compared across the two conditions.

Condition Intervention
Behavioral: Behavioral Activation and Problem Solving Group Therapy
Drug: Guideline Antidepressant Care
Other: LIvelihood Support

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Development of an Integrated Microfinance and Depression Care Program for Women

Resource links provided by NLM:

Further study details as provided by RAND:

Primary Outcome Measures:
  • Change in Depression Score from the Patient Health Questionnaire [ Time Frame: 0, 6, 12 months ] [ Designated as safety issue: No ]
    The PHQ-9 is a nine-item validated tool measuring depressive symptoms based on DSM-IV criteria. The answers are rated on a scale from zero (not at all) to three (nearly every day). Total scores range from 0-27, subdivided into five categories of depression severity: 1 to 4 is minimal; 5 to 9 is mild; 10 to 14 is moderate; 15 to 19 is moderate-severe; and 20 and above is severe. The PHQ-9 has been widely used internationally including in Vietnam.

Secondary Outcome Measures:
  • Change in Quality of Life Score from Quality of Life and Enjoyment and Satisfaction Questionnaire [ Time Frame: 0, 6, 12 months ] [ Designated as safety issue: No ]
    The Quality of Life Enjoyment and Satisfaction Questionnaire is a self-report measure designed to enable investigators to easily obtain sensitive measures of the degree of enjoyment and satisfaction experienced by subjects in various areas of daily functioning. The summary scores were found to be reliable and valid measures of these dimensions in a group of depressed outpatients. The Q-LES-Q measures were related to, but not redundant with, measures of overall severity of illness or severity of depression within this sample. These findings suggest that the Q-LES-Q measures may be sensitive to important differences among depressed patients that are not detected by the measures usually employed.

  • Change in Self-Efficacy Score from Self Efficacy Survey [ Time Frame: 0, 6, 12 months ] [ Designated as safety issue: No ]
    Items were developed to assess effectiveness of a goal-setting and planning intervention (Macleod et al., 2008). Self-efficacy is assessed via 4-items that measure locus of control, materials and skills to complete goals, confidence, and optimism. Self-efficacy is rated on a 9-point scale from 1 ("Not at all") to 9 ("To a great extent").

  • Change in Social Support Index from Medical Outcome Study Social Support Survey [ Time Frame: 0, 6, 12 months ] [ Designated as safety issue: No ]
    A brief, multidimensional, selfadministered, social support survey that was developed for patients in the Medical Outcomes Study (MOS), a two-year study of patients with chronic conditions. This survey was designed to be comprehensive in terms of recent thinking about the various dimensions of social support.

  • Change in health and mental health functioning scores from Medical Outcomes Study Short Form Health Survey (SF-12) [ Time Frame: 0, 6, 12 months ] [ Designated as safety issue: No ]
    The SF-12v2 is a 12-item survey that measures the same eight domains of health. The domains scores are summarized into two composite scores: Physical Component Summary and Mental Component Summary scores. The survey is a brief, reliable measure of overall health status. It is useful in large population health surveys and has been used in Vietnamese populations.

  • Change in Anxiety Symptom Score from Generalized Anxiety Disorder (GAD-7) Scale [ Time Frame: 0, 6, 12 months ] [ Designated as safety issue: No ]
    The GAD-7 is a 7-item anxiety scale used for screening and assessing symptom severity of GAD. GAD and depression symptoms frequently occurred together, but factor analysis confirmed them as distinct dimensions, and they had independent effects on functional impairment and disability. Self-report and interviewer-administered versions of GAD-7 were in good agreement.

  • Change in Behavior Activation Score from the Behavior Activation for Depression Scale Short Form (BADS-SF) [ Time Frame: 0, 6, 12 months ] [ Designated as safety issue: No ]
    The abbreviated BADS-SF is a nine-item scale measuring factors expected to change as a function of behavioral activation, including activation and avoidance

  • Change in household wealth indicators from Economic Well-Being Inventory [ Time Frame: 0, 6, 12 months ] [ Designated as safety issue: No ]
    The economic well-being inventory collect various indicators of self-reported household wealth: housing materials, land ownership, home ownership, and selling and purchasing of assets such as livestock and durable goods (car, bicycle, radio, TV), as well as income, savings, and debt. This economic well-being inventory was used in the Danang Household Mental Health Survey.

  • Change in number and type of income generating activities from the Employment and business Activities Questionnaire [ Time Frame: 0, 6, 12 months ] [ Designated as safety issue: No ]
    We developed questionnaire to measure income generating activities, which include questions about participation and number of hours in types of employment and income generating activities in Low-Income countries, including formal salaried employment, farming and planting food, selling goods and services, property rentals, etc.

  • Treatment Acceptability Score from Help-Seeking Behavior Questionnaire [ Time Frame: 0, 6, 12 months ] [ Designated as safety issue: No ]
    This measure consists of items that assesses 1) resources in the community, 2) participant's help seeking history, 3) perceived effectiveness, and 4) acceptability of a variety of strategies used for depression care.

  • Depression Stigma Score from the Depression Stigma Questionnaire [ Time Frame: 0, 6, 12 months ] [ Designated as safety issue: No ]
    18 item questionnaire about perceived and personal stigma related to depression.

  • Social Capital Score from Social Capital Assessment Tool [ Time Frame: 0, 6, 12 months ] [ Designated as safety issue: No ]
    The short version of the Adapted Social Capital Assessment Tool (SASCAT) is a nine-item tool measures the structural (quantity of social relationships) and cognitive (quality of social relationships) components of social capital as well as citizenship. The measure derived from the Adapted Social Capital Assessment Tool (A-SCAT) (Harpham et al., 2002). The measures has been used in many international settings, including developing countries.

  • Total Score Client Service Satisfaction Questionnaire [ Time Frame: 0, 6, 12 months ] [ Designated as safety issue: No ]
    A standardized measure with strong psychometric properties that could be used to assess general satisfaction across varied health and human services. The CSQ Scales® (CSQ) measure may be used to assess client satisfaction with mental health services, as a program evaluation tool, or to assess client satisfaction within and across programs (intra- or inter-program) and demographic groups.

  • Number of Participants Demonstrating Mental Health Literacy with Depression Vignette [ Time Frame: 0, 12 months ] [ Designated as safety issue: No ]
    Vignette describes someone with the minimal number of symptoms necessary for major depression (according to DSM description). Respondents were asked an open-ended question, ``What would you say, if anything, is wrong with Mary?'' Only answers including " depression " are considered a correct response.

  • Number of Participants with Depression Diagnosis - MINI International Neuropsychiatric Interview, Version 6.0 (MINI) [ Time Frame: 0, 6, 12 months ] [ Designated as safety issue: No ]
    The MINI is a brief structured psychiatric interview used to diagnose for multiple axis I DSM-IV mental disorders. In this study, the MINI is used to assess for major depressive episodes. Using DSM-IV criteria (at least 5 symptoms of depression over a 2 week period; endorsement of depressed mood or anhedonia were necessary for diagnosis) the interviewers can distinguish between past, current, and recurrent episodes of depression. The MINI is a reliable and valid alternative to the longer Structured Clinical Interview for Diagnostic. The MINI has been used widely in developing countries and administered by non-mental health providers.

Estimated Enrollment: 160
Study Start Date: February 2014
Estimated Study Completion Date: April 2016
Estimated Primary Completion Date: September 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: LIFE-DM
Depression and microfinance integrated program using behavior activation and problem solving therapy applied to both depression and livelihood. Livelihood support include microfinance loans, personal finance, and income-generation skills.
Behavioral: Behavioral Activation and Problem Solving Group Therapy
LIFE-DM depression group, uses behavior activation and problem solving therapy skills to teach patients how to manage mood and reach livelihood goals.
Other Name: LIFE-DM Group
Drug: Guideline Antidepressant Care
Guideline antidepressant care
Other Names:
  • Fluoxetine
  • Amitrytaline
  • other antidepressants
Other: LIvelihood Support
Livelihood support, including group-based loans to develop small enterprise, personal finance management education, business management skills, vocational training, and rotating-credit savings program.
Other Name: Microfinance loans
Active Comparator: Treatment as Usual
Currently treatment as usual in this province includes national guidelines for antidepressant care for depression and referral for microfinance/livelihood programs
Drug: Guideline Antidepressant Care
Guideline antidepressant care
Other Names:
  • Fluoxetine
  • Amitrytaline
  • other antidepressants

Detailed Description:

Depression is one of the largest contributors to the world's health burden. Prior work in the Partners in Care study has shown that evidence-based service delivery programs for depression can improve health outcomes in depressed patients, and especially in minorities, largely overcoming disparities in outcomes from care between whites and minorities. Effective treatments exist, but they do not reach many depressed individuals, especially in resource-poor communities--ethnic minorities, rural residents in the United States, and individuals in most of the developing world.

Women, in particular, are at risk for depression and poverty. Integrating programs that treat depression and address livelihood concerns may improve engagement in depression treatment and improve mental health and functioning for patients in low-resource settings. The proposed study would integrate depression care with existing "microfinance" programs, which provide poverty-alleviation services including small loans, savings programs, and vocational training to women.

This project will (1) conduct qualitative studies of barriers and facilitators of women's successful use of existing depression care and microfinance programs; (2) adapt and integrate the depression care and microfinance services; (3) train Women's Union facilitators to deliver the integrated depression care and microfinance program; and conduct evaluation of LIFE-DM program to assess acceptability, feasibility, and preliminary effectiveness. The non-randomized control trial compares the integrated microfinance and collaborative care intervention with enhanced treatment as usual (national guideline antidepressant care and referral to microfinance resources) at the Women's Union in Danang city in Vietnam.


Ages Eligible for Study:   18 Years to 55 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • depression, low-income

Exclusion Criteria:

  • psychosis, mania, substance abuse, high suicide risk, physical disabilities, significant cognitive impairments
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02069301

Hoa Cuong Bac Commune Health Station
Danang, Vietnam
Hoa Cuong Nam Commune Health Station
Danang, Vietnam
Hoa Hiep Nam Commune Health Station
Danang, Vietnam
Hoa Minh Commune Health Station
Danang, Vietnam
Sponsors and Collaborators
National Institute of Mental Health (NIMH)
Danang Psychiatric Hospital
Principal Investigator: Victoria K Ngo, PhD RAND
  More Information

Responsible Party: Victoria K. Ngo, PhD, Behavior Scientist, RAND
ClinicalTrials.gov Identifier: NCT02069301     History of Changes
Other Study ID Numbers: 5R34MH094648-02, 5R34MH094648-02
Study First Received: February 10, 2014
Last Updated: March 3, 2015
Health Authority: United States: Institutional Review Board

Keywords provided by RAND:
Behavior Activation
Problem solving therapy
Depression Treatment
depression care integration

Additional relevant MeSH terms:
Depressive Disorder
Behavioral Symptoms
Mental Disorders
Mood Disorders
Antidepressive Agents
Central Nervous System Agents
Pharmacologic Actions
Psychotropic Drugs
Therapeutic Uses

ClinicalTrials.gov processed this record on October 02, 2015